|
|
Volumn 53, Issue SUPPL. 3, 2003, Pages
|
|
Neuroprotection for Parkinson's disease: Prospects and promises
a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOPAMINE RECEPTOR STIMULATING AGENT;
DRUG METABOLITE;
GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;
LEVODOPA;
NEUROPROTECTIVE AGENT;
NORSELEGILINE;
PRAMIPEXOLE;
PROPARGYLAMINE;
RILUZOLE;
ROPINIROLE;
SELEGILINE;
TOXIN;
UBIQUINONE;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DEGENERATIVE DISEASE;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TARGETING;
EDITORIAL;
ENVIRONMENTAL EXPOSURE;
FETAL TISSUE TRANSPLANTATION;
GENE IDENTIFICATION;
GENE LOCUS;
GENE MUTATION;
GENE THERAPY;
GENETIC SUSCEPTIBILITY;
HUMAN;
MESENCEPHALON;
NERVE DEGENERATION;
NEUROPROTECTION;
NONHUMAN;
PARKINSON DISEASE;
PATHOGENESIS;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
SIDE EFFECT;
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;
AMPHETAMINES;
CLINICAL TRIALS;
GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;
HUMANS;
MONOAMINE OXIDASE INHIBITORS;
NERVE GROWTH FACTORS;
NEUROPROTECTIVE AGENTS;
PARKINSON DISEASE;
SELEGILINE;
|
|
EID: 0037378912
PISSN: 03645134
EISSN: None
Source Type: Journal
DOI: 10.1002/ana.10566 Document Type: Editorial |
|
Times cited : (70)
|
|
References (0)
|